Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
123 hedge funds and large institutions have $408M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 42 increasing their positions, 43 reducing their positions, and 35 closing their positions.
1,926% more call options, than puts
Call options by funds: $3.85M | Put options by funds: $190K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 43
9% less capital invested
Capital invested by funds: $450M → $408M (-$42.6M)
12% less funds holding
Funds holding: 140 → 123 (-17)
49% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$20.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.27M |
| 3 |
BlackRock
New York
|
+$8.91M |
| 4 |
JG
Jefferies Group
New York
|
+$7.26M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$5.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$24.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$21.9M |
| 3 |
State Street
Boston,
Massachusetts
|
-$6.29M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$5.91M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
-$4.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
151
Parallel Advisors
San Francisco,
California
| – | -$5.45K | -641 | -95% |
|
|
GKIM
152
GW&K Investment Management
Boston,
Massachusetts
| – | -$3K | -340 | Closed |
|
|
MAM
153
Meeder Asset Management
Dublin,
Ohio
| – | -$1K | -161 | Closed |
|
|
UB
154
UMB Bank
Kansas City,
Missouri
| – | -$1K | -125 | Closed |
|
|
PHK
155
Point72 Hong Kong
Hong Kong
| – | -$1K | -84 | Closed |
|
156
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$247 | +29 | +126% |
|
DCPH Hedge Fund Activity: Q1 2022 in Review
123 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2022, worth a combined $408M — down 9.5% from $450M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of DCPH and 18 opened new positions — a net loss of 17 holders — while 43 trimmed existing stakes and 42 added.
The largest buyer was Armistice Capital, adding an estimated $20.5M. The largest seller was Goldman Sachs, cutting an estimated $24.1M.
- 123 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2022, down from 140 in Q4 2021.
- Funds reported $408M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 9.5% quarter-over-quarter.
- 18 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 35 closed out, a net change of -17 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Armistice Capital, an estimated $20.5M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Goldman Sachs, an estimated $24.1M sold.
Based on aggregated 13F filings for Q1 2022.